Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) is now available.
Venus Medtech (Hangzhou) Inc. has announced that it has formally submitted all application materials for EU CE MDR marking to a European Notified Body for its Cardiovalve transcatheter tricuspid valve replacement system, a key step toward potential commercialization in Europe. The Cardiovalve System is designed to treat both mitral and tricuspid regurgitation using a transfemoral approach that aims to enhance safety, with a large annulus accommodating up to 55 mm to cover about 95% of patients and a short frame intended to reduce left ventricular outflow tract obstruction risk, positioning the product as a competitive, user-friendly option in the structural heart device market, though the company cautions there is no guarantee it will ultimately reach the market and advises investors to exercise caution.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a China-based medical device company specializing in transcatheter interventional solutions for structural heart diseases. Its portfolio focuses on innovative valve replacement systems targeting conditions such as mitral and tricuspid regurgitation, with a view to serving a broad range of cardiac patients in global markets, including Europe.
Average Trading Volume: 1,905,170
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.09B
Learn more about 2500 stock on TipRanks’ Stock Analysis page.